Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 2.3% – Still a Buy?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)’s share price was up 2.3% during mid-day trading on Wednesday . The stock traded as high as $1.33 and last traded at $1.32. Approximately 179,746 shares traded hands during trading, a decline of 72% from the average daily volume of 645,422 shares. The stock had previously closed at $1.29.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Telomir Pharmaceuticals Stock Up 2.3%

The company’s fifty day moving average price is $1.45 and its two-hundred day moving average price is $1.59. The firm has a market cap of $45.38 million, a PE ratio of -3.57 and a beta of -0.46.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. As a group, analysts predict that Telomir Pharmaceuticals, Inc. will post -0.4 earnings per share for the current year.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Praetorian Wealth Management Inc. acquired a new stake in shares of Telomir Pharmaceuticals during the 3rd quarter valued at approximately $28,000. OneDigital Investment Advisors LLC raised its holdings in Telomir Pharmaceuticals by 64.3% during the third quarter. OneDigital Investment Advisors LLC now owns 23,000 shares of the company’s stock worth $32,000 after purchasing an additional 9,000 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Telomir Pharmaceuticals during the second quarter worth $33,000. Bank of America Corp DE grew its holdings in Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after purchasing an additional 10,880 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Telomir Pharmaceuticals in the second quarter valued at $62,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.